Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.50 |
| ▸ | HTR2B | P41595 | 12/20 | 0.46 |
| ▸ | HTR2A | P28223 | 8/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743799 | 0.87 | HTR2C (0.51) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL5748262 | 0.87 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL5747129 | 0.87 | HTR2C (0.56) | HTR2CHTR2BHTR2AHTR6KDM4E | |
| SCHEMBL5744871 | 0.83 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL5744369 | 0.77 | HTR2C (0.56) | HTR2CHTR2BHTR2AHTR6MEN1 | |
| SCHEMBL5743824 | 0.76 | HTR2C (0.56) | HTR2CHTR2BHTR2AHTR6KDM4E | |
| SCHEMBL5745272 | 0.75 | HTR2C (0.53) | HTR2CHTR2BHTR2AHTR6KDM4E | |
| SCHEMBL6713898 | 0.74 | HTR2C (0.61) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL6715645 | 0.74 | HTR2C (0.61) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL30729380 | 0.70 | MEN1 (0.64) | HTR2CHTR2BHTR2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | ASTELLAS PHARMA INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | ADRA2C, HTR2C, HTR3A | HTR2C 2/4885HTR2B 15/4885HTR2A 5/4885 |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2B 5/4885HTR2A 4/4885 |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | HTR2A, HTR2C, HTR3A | HTR2C 2/4885HTR2B 4/4885HTR2A 1/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HTR2C 1/4885HTR2B 5/4885HTR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.